Atagabalin
Atagabalin (PD 0200390) is a Voltage-gated Calcium channel α2δ subunit binder with an IC50 of 22 nM. Atagabalin regulates neurotransmitter release by inhibiting calcium influx at high neuronal firing rates. Atagabalin can be used in research related to sleep disorders.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 223445-75-8
- Formel: C10H19NO2
- Molecular Weight:185.26
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Alle Calcium Channel Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
Calcium Channel |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | IC50 |
10 μM
Compound: 5
|
Inhibition of L-type amino acid transporter expressed in CHO cells assessed as inhibition of [3H]leucine uptake
Inhibition of L-type amino acid transporter expressed in CHO cells assessed as inhibition of [3H]leucine uptake
|
[PMID: 20005103] |
Atagabalin potently binds to the VGCC α2δ subunit with an IC50 of 22 nM[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 223445-75-8
-
Molecular Weight 185.26
-
Formel C10H19NO2
-
SMILES
O=C(O)CC1(CN)C[C@H](C)[C@@H](C)C1
-
Synonyms
PD 0200390
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
[1]. Kjellsson MC, et al. Modeling sleep data for a new drug in development using markov mixed-effects models. Pharmaceutical research. 2011 Oct;28(10):2610-27. [Content Brief]
[2]. Corrigan B, et al. Effect of renal impairment on the pharmacokinetics of PD 0200390, a novel ligand for the voltage-gated calcium channel alpha-2-delta subunit. British journal of clinical pharmacology. 2009 Aug;68(2):174-80. [Content Brief]
[3]. Chen Y, et al. Review of Voltage-gated Calcium Channel α2δ Subunit Ligands for the Treatment of Chronic Neuropathic Pain and Insight into Structure-activity Relationship (SAR) by Pharmacophore Modeling. Current medicinal chemistry. 2022 Aug 15;29(30):5097-5112. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Atagabalin Related Classifications
HY-14856 Related Classifications
Powered by Bioz
- Atagabalin
- 223445-75-8
- PD 0200390
- PD0200390
- PD-0200390
- Calcium Channel
- renal excretion
- neurotransmitter release
- calcium channel α2δ subunit
- insomnia
- sleep disturbance
- slow-wave sleep
- rapid eye movement sleep
- pharmacophore modeling
- voltage-gated calcium channel alpha-2-delta subunits
- calcium influx
- Inhibitor
- inhibitor
- inhibit